Nano-drug for delivering siBCL11B to treat T-ALL by combining aptamer sgc8 as well as preparation method and application of nano-drug

Delivery of siBCL11B through the nanoparticle complex bound to PAMAM-G5 and sgc8 solves the targeting and delivery efficiency problems in T-ALL treatment, significantly improves the apoptosis rate of T-ALL cells, and provides a new therapeutic approach .

CN119015438AActive Publication Date: 2024-11-26JINAN UNIVERSITY
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202310603407.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-25
Publication Date
2024-11-26
Estimated Expiration
2043-05-25

AI Technical Summary

Technical Problem

The prior art lacks effective targeted treatment options in the treatment of T-ALL, the prognosis of relapsed patients after chemotherapy-induced remission is extremely poor, and the delivery effect of RNAi in hematologic tumors is limited, especially when used in vivo, there is an immune response and targeting. The problem of sexual inadequacy.

Method used

The nanoparticle complex prepared by PAMAM-G5 and nucleic acid complex, combined with sgc8 as a nucleic acid aptamer and siBCL11B, and the delivery of siBCL11B is achieved by targeting PTK7 in T-ALL cells, promoting tumor cell apoptosis.

Benefits of technology

Improve the targeting and anti-tumor efficiency of nanoparticle complexes, reduce the impact on normal cells, significantly knock down the expression of BCL11B in T-ALL cells, promote tumor cell apoptosis, and provide a new clinical Treatment pathway.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015438A_ABST
    Figure CN119015438A_ABST
Patent Text Reader

Abstract

The invention discloses a nano-drug for delivering siBCL11B to treat T-ALL by combining with an aptamer sgc8 as well as a preparation method and application of the nano-drug. Acute T cell lymphocytic leukemia cells Molt4 and CCRF-CEM are used as research objects, the nano-drug is delivered through experimental operations such as in-vitro dosing, and the cell activity and the cell apoptosis condition are measured. The result shows that the nano-drug can effectively and stably transfect and deliver the siBCL11B into the T-ALL tumor cell strain and successfully release the siBCL11B, and the expression of the BCL11B in the T-ALL cell strain is knocked down, so that the apoptosis of the tumor cell strain is promoted, and the activity of the tumor cell strain is inhibited. Based on the result, the nano-drug can be used for delivering siBCL11B so as to be used for clinical treatment of acute T cell lymphocytic leukemia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to a nano drug for treating T-ALL by delivering siBCL11B in combination with an aptamer sgc8, as well as a preparation method and application thereof. Background Art

[0002] In the treatment of hematological malignancies, chemotherapy-induced remission has always been the main treatment method. Chemotherapeutic drugs for hematological malignancies usually have the effect of inhibiting DNA synthesis or destroying DNA structure. When the damage exceeds the tumor cell's ability to repair itself, it can activate programmed cell death, thereby inducing remission. However, chemotherapy drugs also have toxic side effects on normal cells. Patients often cannot withstand the double blow of tumors and chemotherapy and have a poor prognosis. 1,2 . In addition, it has been found in clinical treatment that under the selection pressure of chemotherapy drugs, potential resistant cells gradually replace sensitive cells to become the dominant clones. Relapse after chemotherapy remission often indicates the failure of the original chemotherapy regimen and a poor prognosis. Although multi-drug combination chemotherapy can increase the proportion of induced remission and reduce the number of resistant cells caused by single pharmacological mechanisms, some patients still fail after chemotherapy. Therefore, in recent years, scientific research on hematological malignancies has been looking for molecular targets that are specifically and highly expressed in tumor cells to combat and treat hematological malignancies, and as an alternative after the failure of first-line chemotherapy. 3 . Based on the rapid development of genomics, the research on the targets of hematological malignancies has gradually been refined to the gene level. The research on targeted therapy of hematological malignancies has also gradually achieved clinical therapeutic effects, such as the use of rituximab to target CD20 in the treatment of lymphoma. The development of drugs with new targets may be a new way to treat patients with hematological malignancies who have failed chemotherapy-induced remission.

[0003] Acute T-cell lymphoblastic leukemia (T-ALL) is an aggressive, heterogeneous blood malignancy that originates from the developmental arrest of T-cell precursors at a specific maturation stage, the blockage of differentiation and the uncontrolled proliferation. It accounts for 25% of acute lymphoblastic leukemia in adults and 15% in children. 4 . The clonal primitive cells in the bone marrow of T-ALL continue to proliferate and squeeze the normal hematopoietic environment, causing a decrease in normal hematopoiesis of the three lineages, including erythropenia, thrombocytopenia and granulocytopenia. T-ALL tumor cells also often accumulate in different extramedullary organs such as the liver, spleen and lymph nodes, especially those with infiltration of the central nervous system, which has a very poor prognosis. T-ALL is associated with the loss of many tumor suppressor pathways, such as the inactivation of PTEN and CDKN2A / B, and the activation of tumor-promoting pathways, such as the activation of NOTCH1 and IL7R / JAK / STAT. 5Although most T-ALL patients can achieve remission after chemotherapy induction and are expected to be cured after allogeneic stem cell transplantation, about 20-30% of patients still relapse after remission. The prognosis of patients who relapse is extremely poor and there is currently no effective targeted treatment for T-ALL. 6 Therefore, it is still an urgent task to find new specific targets, discover drugs and programs with greater therapeutic potential, and improve the survival rate and cure rate of such patients.

[0004] BCL11B (B-cell chronic lymphocytic leukemia / lymphoma 11B) is a gene located at 14q32.2 that encodes a C2H2 zinc finger protein transcription factor. It belongs to the BCL family together with BCL11A and is an important factor regulating lymphocyte proliferation and survival. It is expressed in the nervous system, thymus and lymphocytes and is highly expressed in some T-ALL patients. 7 The BCL11B gene has 4 exons and 4 transcripts have been identified, of which exon 3 is involved in encoding transcripts 1 and 3 but not in encoding transcripts 2 and 4. 8 Existing studies have shown that BCL11B plays a very important role in the normal differentiation and development of T cells and is a key gene for T cell directional differentiation. BCL11B is first expressed in DN2 7 . BCL11B is believed to promote the expression of T cell lineage genes and shut down the expression of myeloid cell and NK cell lineage genes to promote T cell directional differentiation. NOTCH1 signaling is also crucial for the normal differentiation and development of T cells. BCL11B has been reported to be downstream of NOTCH1 regulation and is involved in the differentiation and development of T cells. In a considerable number of patients with T cell-derived leukemias such as T-ALL and TCL, BCL11B expression is higher than that of normal T cells, but there are also some patients with T cell-derived leukemias whose tumor cells do not have significantly increased BCL11B expression. At the same time, in AML and other non-T cell-derived leukemias, there is also an increase in BCL11B expression in 15% of cases. These patients are identified and defined as BCL11B-activated leukemias with specific gene expression characteristics. 9,10 . The study believes that the BCL11B gene of these patients is mutated, and the fusion of BCL11B coding with the strong promoter of other oncogenes leads to increased BCL11B expression, further amplifying the downstream pathway of BCL11B. Studies on the downstream of BCL11B have reported that it promotes the expression of anti-apoptotic genes such as BCLxL and inhibits the expression of apoptotic genes such as TRAIL. At the same time, BCL11B has also been reported to interact with histone modification complexes such as NuRD, and participate in epigenetic regulation such as histone deacetylation.11 It has been reported that the effects of BCL11B long transcripts and short transcripts in T-ALL tumor cell lines are different, and the expression pattern is also different from that of normal T cells, which may play a role in the occurrence and development of tumors. These studies all indicate that BCL11B may play an important key role in the occurrence and development of T-ALL. 12 . Moreover, BCL11B may not simply be reflected in changes in gene expression levels, but may involve changes such as variable splicing of transcripts that affect the function of BCL11B. BCL11B relies on its transcription factors to regulate gene expression levels and interact with NuRD to play an epigenetic regulatory role. Whether it is normally expressed in T-ALL also affects the occurrence and development of T-ALL.

[0005] RNA interference technology (RNA interfering, RNAi) uses a single-stranded RNA specific sequence to bind to the homologous sequence on the mRNA and induce mRNA degradation to silence the expression of the gene. Scientific research has discovered this phenomenon in mammalian cells and silenced the expression of specific genes through artificially synthesized small interfering RNA (small interfering RNA, siRNA) and transfected into cells. It has the characteristics of high efficiency and good targeting. The research group of Professor Li Peng from the Institute of Hematology of Jinan University and the Guangzhou Institute of Health of the Chinese Academy of Sciences and Professor Grzegorz K Przybylski from Poland have confirmed in previous studies that electroporation of siBCL11B in T-ALL tumor cell lines can promote tumor cell apoptosis and inhibit tumor cell proliferation, and has little effect on normal human T cells. 13-15 Therefore, targeting BCL11B to treat T-ALL may be a potential alternative after the failure of clinical induction chemotherapy. However, due to the widespread presence of nucleases in circulating blood and liver, the simple intravenous injection of small molecule nucleic acids has a poor therapeutic effect, and electrotransfection does not have clinical therapeutic significance. Liposome transfection is far less effective than solid tumors in the treatment of hematological tumors. Therefore, the treatment of mature RNAi in hematological tumors has limited progress and effect.

[0006] Among the polymer materials for delivering small molecule nucleic acids, PAMAM (Polyamindoamine) is a polyamide-amine dendrimer. A large number of -NH2 groups in its molecules can attract and spontaneously combine with the P atoms in the nucleic acid molecules through electrostatic adsorption, and at the same time play a role in blocking the epitopes that nucleases degrade nucleic acids, stabilizing the existence time of nucleic acids in the peripheral blood environment. 16In existing reports, PAMAM has been used to deliver a variety of small molecule nucleic acids and has a certain effect. It is an ideal material for delivering nucleic acid molecules into cells. However, PAMAM does not have targeting selectivity for different cells, so there are limitations in its application. 17,18 PAMAM-G5 refers to PAMAM with 5 branches. Aptamers are a type of single-stranded nucleic acid molecules that can spontaneously form secondary structures. Their secondary structures can bind to other molecules such as protein molecules, similar to the specificity of antigen-antibody binding. 19,20 . Nucleic acid molecules have a lower risk of immune response when used in vivo because their immunogenicity is lower than that of protein molecules. Sgc8 is a single-stranded DNA nucleic acid aptamer screened and identified by Professor Tan Weihong of Hunan University. Its specific secondary structure can specifically bind to the cell membrane protein PTK7 (protein tyrosine kinase 7). PTK7 is highly expressed in T cells and T-ALL tumor cell lines. Sgc8 enters the cell after binding to PTK7 through endocytosis. In the reported application cases of PAMAM and aptamers, more designs are designed for the detection of tumor cells. When applied to tumor treatment, PAMAM is more often chemically combined with chemotherapy drugs such as daunorubicin, rituximab, cytarabine and other drugs, assisted by protein molecules such as FLT3L and anti-CD20 antibodies or nucleic acid molecules such as TD05 and sgc8 to improve the specificity of the complex. In blood tumors, especially T-ALL, there are currently very limited reports on the use of PAMAM combined with sgc8 to improve the specificity of nanoparticles and deliver siRNA to treat tumors. There is even less effective evidence and attempts for in vivo experiments that simulate the natural course of blood tumors. Therefore, we hope to use sgc8 to improve the specificity of nanomedicines based on the discovery of BCL11B as a potential target for the treatment of T-ALL in previous work. We designed nanoparticles that combine sgc8 to deliver siBCL11B in this patent, and tested the anti-tumor effect of the nanomedicine designed in this patent by simulating the way of clinical chemotherapy administration in in vivo experiments that are closer to the clinical T-ALL state, providing a higher level of evidence for the clinical application of the nanomedicine designed in this patent.

[0007] References:

[0008] 1 Cao,S.C.et al.Effect of chemotherapy(with and without radiotherapy)on the intelligence of children and adolescents treated for acutelymphoblastic leukemia;a meta-analysis.Psychooncology32,492-505,doi:10.1002 / pon.6103(2023).

[0009] 2 Sliwa-Tytko,P.,Kaczmarska,A.,Lejman,M.&Zawitkowska,J.NeurotoxicityAssociated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy andImmunotherapy.Int J Mol Sci23,doi:10.3390 / ijms23105515(2022).

[0010] 3 Zeng,X.L.,Heneghan,M.B.&Badawy,S.M.Adherence to Oral Chemotherapyin Acute Lymphoblastic Leukemia during Maintenance Therapy in Children,Adolescents,and Young Adults:A Systematic Review.Curr Oncol30,720-748,doi:10.3390 / curroncol30010056(2023).

[0011] 4 Thomas,X.T-cell acute lymphoblastic leukemia:promising experimentaldrugs in clinical development.Expert Opin Investig Drugs32,37-52,doi:10.1080 / 13543784.2023.2161361(2023).

[0012] 5 Martelli,A.M.et al.Understanding the Roles of the HedgehogSignaling Pathway during T-Cell Lymphopoiesis and in T-Cell AcuteLymphoblastic Leukemia(T-ALL).Int J Mol Sci24,doi:10.3390 / ijms24032962(2023).

[0013] 6 Caracciolo,D.et al.The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia:advances,challenges and futureperspectives.Exp Hematol Oncol12,5,doi:10.1186 / s40164-022-00368-w(2023).

[0014] 7 Chen,S.et al.The role of BCL11B in regulating the proliferation ofhuman naive T cells.Hum Immunol73,456-464,doi:10.1016 / j.humimm.2012.02.018(2012).

[0015] 8 Grabarczyk,P.et al.The N-Terminal CCHC Zinc Finger Motif MediatesHomodimerization of Transcription Factor BCL11B.Mol Cell Biol38,doi:10.1128 / MCB.00368-17(2018).

[0016] 9 Kominami,R.Role of the transcription factor Bcl11b in developmentand lymphomagenesis.Proc Jpn Acad Ser B Phys Biol Sci88,72-87,doi:10.2183 / pjab.88.72(2012).

[0017] 10 Li,X.H.X.D.Y.The role of BCL11B in hematologicalmalignancy.Experimental Hematology&Oncology (2012).

[0018] 11 Sidwell,T.&Rothenberg,E.V.Epigenetic Dynamics in the Function ofT-Lineage Regulatory Factor Bcl11b.Front Immunol12,669498,doi:10.3389 / fimmu.2021.669498(2021).

[0019] 12 Montefiori,L.E.&Mullighan,C.G.Redefining the biological basis oflineage-ambiguous leukemia through genomics:BCL11B deregulation in acuteleukemias of ambiguous lineage.Best Pract Res Clin Haematol34,101329,doi:10.1016 / j.beha.2021.101329(2021).

[0020] 13 Huang,X.et al.Down regulation of BCL11B expression inhibitsproliferation and induces apoptosis in malignant T cells by BCL11B-935-siRNA.Hematology16,236-242,doi:10.1179 / 102453311X13025568941961(2011).

[0021] 14 Shen,Q.et al.BCL11B suppression does not influence CD34(+)celldifferentiation and proliferation.Hematology17,329-333,doi:10.1179 / 1024533212Z.000000000145(2012).

[0022] 15 Li,K.et al.Inhibition of BCL11B induces downregulation of PTK7 andresults in growth retardation and apoptosis in T-cell acute lymphoblasticleukemia.Biomark Res9,17,doi:10.1186 / s40364-021-00270-3(2021).

[0023] 16 Arkas,M.,Vardavoulias,M.,Kythreoti,G.&Giannakoudakis,D.A.DendriticPolymers in Tissue Engineering:Contributions of PAMAM,PPI PEG and PEI toInjury Restoration and Bioactive Scaffold Evolution.Pharmaceutics15,doi:10.3390 / pharmaceutics15020524(2023).

[0024] 17 Kheraldine,H.et al.Emerging innate biological properties of nano-drug delivery systems:A focus on PAMAM dendrimers and their clinicalpotential.Adv Drug Deliv Rev178,113908,doi:10.1016 / j.addr.2021.113908(2021).

[0025] 18 Li,J.,Liang,H.,Liu,J.&Wang,Z.Poly(amidoamine)(PAMAM)dendrimermediated delivery of drug and pDNA / siRNA for cancer therapy.Int J Pharm546,215-225,doi:10.1016 / j.ijpharm.2018.05.045(2018).

[0026] 19 Tarach, P. & Janaszewska, A. Recent Advances in Preclinical Research Using PAMAM Dendrimers for Cancer Gene Therapy. Int J Mol Sci22, doi:10.3390 / ijms22062912(2021).

[0027] 20 Wong, KH, Guo, Z., Law, MK & Chen, M. Functionalized PAMAM constructed nanosystems for biomacromolecule delivery. Biomater Sci11, 1589-1606, doi:10.1039 / d2bm01677j(2023). Summary of the invention

[0028] The purpose of the present invention is to overcome the deficiencies in the prior art and provide a nanoparticle composite.

[0029] Another object of the present invention is to provide a method for preparing the above-mentioned nanoparticle composite.

[0030] Another object of the present invention is to provide the use of the above-mentioned nanoparticle complex in the preparation of a drug for treating acute T-lymphocytic leukemia.

[0031] In order to achieve the above-mentioned object of the invention, the present invention adopts the following technical solutions:

[0032] A nanoparticle complex is prepared by combining a polyamide-amine dendritic polymer with nucleic acid, wherein the nucleic acid is an aptamer sgc8 and siBCL11B; and the siBCL11B refers to siRNA that targets and inhibits the BCL11B gene.

[0033] Furthermore, the polyamidoamine dendritic polymer is selected from PAMAM-G5.

[0034] Furthermore, the sequence of the aptamer sgc8 is 5'-ATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGTTAGA-3'.

[0035] Furthermore, the sequence of the siBCL11B is 5'-GCACAACAUGCAAGCAGCCCUUCAA-3'.

[0036] Furthermore, the molar ratio of the polyamidoamine dendrimer to the nucleic acid is 2 to 4:1, preferably 3:1.

[0037] Furthermore, the molar ratio of the aptamer sgc8 to siBCL11B is 3-5:1, preferably 4:1.

[0038] The method for preparing the nanoparticle complex is to fully mix the polyamide-amine dendrimer solution, the aptamer sgc8 solution and the siBCL11B solution, centrifuge them instantaneously, and incubate them at room temperature to form a stable nanoparticle structure.

[0039] Furthermore, the incubation time is 5±1 min.

[0040] The room temperature in the present invention refers to 15-30°C.

[0041] Application of the nanoparticle complex in the preparation of medicine for treating acute T lymphocytic leukemia.

[0042] The present invention combines the characteristics of high expression of BCL11B in T-ALL cells and the structural and functional characteristics of siRNA, PAMAM and sgc8, constructs a novel nanoparticle structure of spontaneously formed PAMAM+siBCL11B+sgc8 for treating T-ALL, uses sgc8 to increase the targeting of nanoparticles, uses PAMAM to protect and deliver siBCL11B, and uses siBCL11B to promote apoptosis of T-ALL tumor cells, providing a new approach for the clinical treatment of T-AZLL.

[0043] Compared with the prior art, the present invention has the following advantages and effects:

[0044] (1) Both siRNA and aptamers are nucleic acid molecules with low immunogenicity, high safety for in vivo use, and low adverse reactions. The preparation of nanoparticle drugs is simple and efficient. sgc8 targeting T-ALL tumor cells can improve the anti-tumor efficiency of the drug, reduce the drug dosage, and give full play to the clear and effective effect of siBCL1B in promoting T-ALL tumor apoptosis.

[0045] (2) The present invention uses acute T-cell lymphoblastic leukemia cells Molt4 and CCRF-CEM as research objects, administers different siBCL11B delivery combinations through in vitro drug addition and other experimental operations, and measures the cell viability and apoptosis. The results show that PAMAM can effectively and stably transfect and deliver siBCL11B into T-ALL tumor cell lines and successfully release siBCL11B, knocking down the expression of BCL11B in T-ALL cell lines, thereby promoting apoptosis of tumor cell lines and inhibiting the viability of tumor cell lines. Based on this result, the new nucleic acid delivery structure can be used to deliver siBCL11B for the clinical treatment of acute T-cell lymphoblastic leukemia. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 This is a schematic diagram of the composite construction of nanoparticles of the present invention.

[0047] Figure 2 This is a verification diagram of the optimal ratio of PAMAM-G5, siBCL11B and sgc8.

[0048] Figure 3 Cellular sublocalization mapping of nucleic acid delivery by nanoparticle complexes was validated for confocal microscopy.

[0049] Figure 4 RT-PCR validation of BCL11B mRNA level changes 48 hours after Molt4 cells and CCRF-CEM cells were transfected with nanoparticle complexes.

[0050] Figure 5 Western blot validation of BCL11B protein level changes 48 hours after Molt4 cells and CCRF-CEM cells were transfected with nanoparticle complexes.

[0051] Figure 6 This is a graph showing the change in apoptosis ratio detected by flow cytometry 48 hours after Molt4 cells were transfected with nanoparticle complexes.

[0052] Figure 7 This is a graph showing the changes in cell proliferation activity detected by CCK-8 48 hours after Molt4 cells were transfected with nanoparticle complexes.

[0053] Figure 8 This is a graph showing the change in cell apoptosis ratio detected by flow cytometry 48 hours after CCRF-CEM cells were transfected with nanoparticle complexes.

[0054] Fig. 9 This is a graph showing changes in cell proliferation activity detected by CCK-8 48 hours after CCRF-CEM cells were transfected with nanoparticle complexes.

[0055] Fig.10This is a graph showing the results of a study using flow cytometry to detect the expression ratio of human CD45 in bone marrow cells of each group.

[0056] Fig.11 This is a study result showing the effect of nanoparticle complex transfection on apoptosis of normal T cells 48 hours after detection by flow cytometry. DETAILED DESCRIPTION

[0057] The present invention is further described in detail below in conjunction with embodiments and drawings, but the embodiments of the present invention are not limited thereto.

[0058] Example 1

[0059] 1. Experimental Materials and Methods

[0060] 1. Experimental Materials

[0061] (1) Molt4 and CCRF-CEM cell lines were purchased from the American Type Culture Collection (ATCC).

[0062] (2) siBCL11B and cy5-modified siBCL11B (hereinafter referred to as siBCL11B-cy5, the sequence of siBCL11B is GCACAACAUGCAAGCAGCCCUUCAA) were delivered to Guangzhou Ruibo Company for synthesis of dry powder, dissolved in DEPC water and prepared into 100 μmol / L storage solution, and then stored at -80°C in aliquots. sgc8 and FAM-modified sgc8 (hereinafter referred to as sgc8-FAM, the sequence of sgc8 is 5'-ATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGTTAGA-3') were delivered to Guangzhou Ruibo Xingke Company for synthesis of dry powder, dissolved in DEPC water and prepared into 100 μmol / L storage solution, and then stored at -80°C in aliquots. PAMAM-G5 was purchased from Shandong Weihai Chenyuan Molecular New Materials Co., Ltd., dissolved in DMSO and prepared into 100 μM storage solution, and then stored at 4°C.

[0063] (II) Experimental methods

[0064] (1) Cell culture

[0065] ①Molt4 cells: The complete culture medium is 90% RPMI-1640 medium containing 10% Gibco fetal bovine serum, penicillin (100U / mL) and streptomycin (100mg / mL); culture in a 5% CO2 concentration, 37℃ constant temperature incubator. The cells are suspension cells and their density is maintained at 1-2×10 6 / mL to ensure that the cells are in the logarithmic growth phase, and the cells are passaged every 2-3 days on average.

[0066] ②CCRF-CEM cells: The complete culture medium is 90% RPMI-1640 medium containing 10% Gibco fetal bovine serum, penicillin (100U / mL) and streptomycin (100mg / mL); cultured in a 5% CO2 concentration, 37°C constant temperature incubator. The cells are suspension cells and their density is maintained at 1-2×10 6 / mL to ensure that the cells are in the logarithmic growth phase, and the cells are passaged every 2-3 days on average.

[0067] (2) Construction of Nanoparticle Complexes

[0068] Use high-pressure sterilized 1×PBS to filter through a 0.22 μm filter membrane for later use, and thaw siBCL11B and sgc8 and place them on ice for later use.

[0069] ① Determine the optimal nitrogen-phosphorus ratio (NP ratio) of PAMAM-G5 and nucleic acids

[0070] Take 100 μmol / L stock solutions of PAMAM-G5 and siBCL11B, dilute them to 100 nmol / L respectively, extract 1 μL of 100 nmol / L siBCL11B as 1 unit, extract 0.5 μL, 1 μL, 2 μL, and 3 μL of 100 nmol / L PAMAM-G5 respectively, mix them into separate 0.2 mL sterile enzyme-free EP tubes, make up the volume of each group to 20 μL with 1× PBS, fully mix the reagents in each tube to prepare a gradient concentration mixture, incubate at room temperature for 5 min, and then add 3 μL of 6× loading The buffer was mixed again, 10 μL was extracted and added to the 1% agarose gel loading tank, and the control well samples of PAMAM-G5 and siBCL11B were added at the same time. The electrophoresis was performed in 1×TAE electrophoresis buffer at a constant voltage mode of 80 V for 30 min. The agarose gel was taken out and placed under UV development to observe the packaging efficiency of PAMAM-G5 and siBCL11B at different ratios. In the present invention, the optimal ratio was PAMAM: nucleic acid = molar ratio of 3:1 (i.e., nitrogen-phosphorus ratio of 30:1).

[0071] ② Construction of nanoparticle complexes for cell experiments after preparation according to the optimal NP ratio

[0072] 100 μmol / L PAMAM-G5, 100 μmol / L siBCL11B and 100 μmol / L sgc8 were thawed and placed at 4°C for later use.

[0073] The experiment set up a blank control group Contrl (CTR), PAMAM-G5 alone group (PAMAM), PAMAM-G5 packaged sgc8 group (PAMAM+sgc8), PAMAM-G5 packaged siBCL11B group (PAMAM+siBCL11B), and PAMAM-G5 packaged siBCL11B and sgc8 group (PAMAM+siBCL11B+sgc8). The reagents for the five groups were prepared in sterile enzyme-free 1.5 mL EP tubes. 0 μL, 15 μL, 15 μL, 15 μL, 15 μL were added to 100 μmol / L PAMA-G5, 0 μL, 0 μL, 5 μL, 0 μL, 1 μL were added to 100 μmol / L sgc8, 0 μL, 0 μL, 5 μL, 1 μL were added to 100 μmol / L siBCL11B, and the volume was made up to 50 μL with 1× PBS. After thorough mixing, the tubes were centrifuged instantly and incubated at room temperature for 5 min to form a stable nanoparticle structure, and finally added to a 50*10 4 The cells were incubated in 1 mL of culture medium of Molt4 or CCRF-CEM cells at 37°C for 48 h, and then the cells were collected for subsequent experimental detection. In this system, the final concentrations of PAMAM-G5 were 0 μmol / L, 1.5 μmol / L, 1.5 μmol / L, 1.5 μmol / L, 1.5 μmol / L, sgc8 were 0 μmol / L, 0 μmol / L, 0.5 μmol / L, 0.1 μmol / L, and siBCL11B were 0 μmol / L, 0 μmol / L, 0 μmol / L, 0.5 μmol / L, 0.4 μmol / L.

[0074] (3) Detection of the effect of nanoparticle nucleic acid delivery (in this part of the experiment, siBCL11B was modified with cy5 and sgc8 was modified with FAM)

[0075] Add the nanoparticle complex to the culture medium of Molt4 / CCRF-CEM cells 20 hours after incubation. Add 1:10000 Hoechst33258 and incubate overnight. Collect the cells into a 1.5mL centrifuge tube at 24 hours, centrifuge at 350rcf for 5 minutes at room temperature, resuspend with 1mL 1×PBS, centrifuge at 350rcf for 5 minutes at room temperature, wash with 1×PBS for 3 times, resuspend the cells with 100μL 1×PBS, add to the plate of the spinner, centrifuge at 200rcf for 10 minutes at room temperature to obtain a cell spin. Gently absorb the residual liquid on the slide with filter paper, add 100μL immunofluorescence fixative to each slide, incubate at 4℃ with the light off for 12 hours, remove the liquid on the slide with a pipette, rinse gently with 1mL 1×PBS, and absorb the residual liquid with filter paper, repeat the washing 3 times. After absorbing the residual liquid, 100 μL of immunofluorescence preservation solution was added to each slide, and the slides were sealed with coverslips. After being fixed with clips for half an hour, cell fluorescence images were detected and taken under a confocal microscope at 555 nm, 488 nm and DAPI channels.

[0076] (4) siBCL11B delivery effect detection

[0077] ①RT-PCR detection of BCL11B expression changes at the transcriptional level

[0078] Collect cells to extract RNA: Add the nanoparticle complex to the Molt4 / CCRF-CEM cell culture medium after incubation for 48 hours, collect the cells into a 1.5mL centrifuge tube, centrifuge at 350rcf for 5min at room temperature, resuspend with 1mL 1×PBS, and centrifuge at 350rcf for 5min at room temperature. Repeat the washing with 1×PBS for 2 times, remove the supernatant and add 1mL Trizol reagent, shake well to lyse the cells. Add 200μL chloroform to the cell lysate, mix it upside down for dozens of times, and then stand at room temperature to wait for stratification. Centrifuge at 4℃13400rcf for 30min, take 500μL of the upper aqueous phase after stratification and transfer it to a new 1.5EP tube, add 500μL isopropanol, mix well and place it at -20℃ overnight. After overnight, centrifuge the sample at 4°C, 12000rcf for 10 min, remove the supernatant, add 1mL of anhydrous ethanol to resuspend the precipitate, centrifuge at 4°C, 12000rcf for 10 min, remove the supernatant, repeat the wash with anhydrous ethanol, and remove the ethanol. Place the RNA precipitate on ice to dry for a while, add 50μL of DEPC water to resuspend and dissolve the RNA aqueous solution, and store it at -20°C for later use.

[0079] Reverse transcription was used to obtain cDNA and RT-PCR was used to detect the expression changes of BCL11B: 1 μg of total RNA was reverse transcribed into 20 μL of cDNA using TAKARA's reverse transcription kit, which was diluted with 20 μL of DEPC water and used as a template for RT-PCR. Tiangen's quantitative kit was used on a bio-rad fluorescent PCR instrument with GAPDH as the internal reference gene to detect and read the expression cycle values ​​of BCL11B between groups. Three replicate wells were set up for each group to observe the changes.

[0080] ② Western blot detection of BCL11B expression changes at the protein level

[0081] Collect cells to obtain protein samples: add the Molt4 / CCRF-CEM cell culture medium that has been incubated with the nanoparticle complex for 48 hours, collect the cells into a 1.5 mL centrifuge tube, centrifuge at 350 rcf for 5 min at room temperature, resuspend with 1 mL of 1×PBS, and centrifuge at 350 rcf for 5 min at room temperature, repeat washing with 1×PBS for 2 times, remove the supernatant and add 100 μL of Biyuntian 1×SDS loading buffer, centrifuge the sample after fully lysing it, place it on a metal heating shaker at 100°C to denature the protein sample for 10 min, and store it at 80°C for later use after cooling.

[0082] Western blot detection of BCL11B expression changes in protein samples: GAPDH was used as the internal reference protein expression to adjust the sample loading amount, and the protein samples were vertically electrophoresed in 10% SDS PAGE gel at 90V for 120min. After the electrophoresis, the excess area of ​​the SDS PAGE gel was cut off, and the protein in the gel was transferred to the 0.45μm PVDF membrane of millipore at 20V for 30min using the semi-dry transfer buffer of Beyotime. The PVDF membrane was rotated and blocked in 5% BSA blocking solution at 4℃ for 4h, and the band positions of BCL11B and GAPDH were cut out according to the size of the protein marker and transferred to the primary antibody dilution solution containing 1:5000 BCL11B (CST, rabbit antibody) and GAPDH (Beyotime, mouse antibody) and incubated overnight at 4℃. After recovering the primary antibody dilution, wash with 3 mL of 1×TBST at room temperature for 3 min, repeat the wash 3 times, replace with the corresponding 1:10000 secondary antibody dilution, incubate with rotation at room temperature for 2 h, then recover the secondary antibody dilution, wash with 3 mL of 1×TBST at room temperature for 3 min, repeat the wash 3 times, add biosharp chemiluminescence detection substrate when the PVDF membrane is not obviously dry, expose and photograph the protein bands in the developer, and observe the changes.

[0083] (5) Flow cytometry to detect cell apoptosis

[0084] Add the nanoparticle complex to the Molt4 / CCRF-CEM cell culture medium after 48 hours of incubation, collect the cells into a 1.5mL centrifuge tube, centrifuge at 350rcf for 5min at room temperature, resuspend with 1mL of 1×PBS, and centrifuge at 350rcf for 5min at room temperature. According to the instructions of the Lianke apoptosis kit, each group was resuspended with 100μL 1X binding buffer, and 1μL of AnnexinV antibody and 0.5μL of Propidine iodide (PI) antibody solution were added. After gently blowing and mixing with the cells, incubate at room temperature in the dark for 5min, and then detect the cell fluorescence of APC and PE channels on Agilent's 6-color flow cytometer. The experimental results were analyzed using FlowJo software and the proportional data were output.

[0085] (6) CCK-8 detection of cell activity

[0086] Add the nanoparticle complex to the Molt4 / CCRF-CEM cell culture medium after 48 hours of incubation, collect the cells into a 1.5 mL centrifuge tube, centrifuge at 350 rcf for 5 min at room temperature, resuspend in 1 mL of complete culture medium, count, and dilute to 50*10 4 / mL, extract 100μL of cell suspension and add it to a 96-well plate so that each well has 5*10 4 Cells were added to each well, and blank culture medium wells without cells were set for baseline correction. Three replicate wells were set for each group. 10 μL of biosharp CCK-8 reagent was added to each well and the well plate was gently mixed. After returning to the incubator at 37°C for 4 hours, the value was read at a wavelength of 450 nm using an ELISA reader to observe the results. The read value was deducted from the blank culture medium value, and the blank control group was set as 1, and the following formula was used to calculate: cell activity = (treated group - blank control group) / (blank group).

[0087] (7) Animal experiments

[0088] We ordered immunodeficient mice BND-G from Zhuhai Baishitong Company, 5 weeks old. After quarantine, 300*10e6 cells of T-ALL PDX cells donated by Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences were injected into the circulating blood of mice through tail vein injection. On the 7th day, 100ul of orbital blood was collected and placed in a 1.5EP tube with 200ul of 1XPBS containing 2mM EDTA and mixed thoroughly to prevent coagulation. After centrifugation at 500rcf for 5min, the supernatant was removed. 1mL of red blood cell lysis buffer (biosharp, BL503B) was added to the EP tube to resuspend, incubate at room temperature in the dark for 15min, and mix once every 5min. After the red blood cell lysis was completed, the supernatant was removed after centrifugation at 500rcf for 5min. 1mL of 1X PBS was added to the EP tube to resuspend, centrifuge at 500rcf for 5min, and the supernatant was removed. Washing was repeated once. Prepare 200ul 1X PBS + 5ul CD45-FITC (Biolegend, 304038) mixed solution for each sample, resuspend and incubate at room temperature in the dark for 15min, add 1mL 1X PBS to the EP tube for resuspending, centrifuge at 500rcf for 5min, remove the supernatant, add 200ul 1X PBS and use flow cytometry to detect the expression ratio of human CD45 in peripheral blood. If it exceeds 5%, the modeling is successful. According to the blank control group Contrl (CTR), PAMAM-G5 alone group (PAMAM), PAMAM-G5 packaged sgc8 group (PAMAM+sgc8), PAMAM-G5 packaged siBCL11B group (PAMAM+siBCL11B), PAMAM-G5 packaged siBCL11B and sgc8 group (PAMAM+siBCL11B+sgc8), the animal experiment drugs were based on the nanoparticle mass of 5 mg / kg, the molar ratio of PAMAM-G5 to nucleic acid was 3:1, and the mass ratio was about 6.3:1. The drugs were injected into the tail vein every 2 days. After 3 consecutive weeks, the survival information of the mice was recorded. The experimental endpoint was 2 weeks after drug withdrawal. The experiment was stopped and the mice were killed by CO2 asphyxiation. The spleen and femoral tissues of the mice were dissected. One of the femurs was taken with a syringe to extract 1X After PBS, the long diameter of the femur was punctured and the cells in the bone marrow were flushed out and collected into an EP tube. The same steps as the previous red blood cell lysis and CD45 flow staining were used to detect the expression ratio of human CD45 in the bone marrow to reflect the tumor load. The long diameter and short diameter of the spleen were measured, which also reflected the tumor load. The spleen and the remaining femur were placed in 3mL 4% paraformaldehyde (Biyuntian, P0099-500ml) and fixed for 48 hours and then sent to Guangzhou Bolf Biological Company for tissue sectioning and subsequent HE staining and BCL11B immunohistochemical staining (CST, 12120S) to detect the changes in T-ALL tumor infiltration in the spleen and bone marrow after nano-drug intervention and the changes in BCL11B expression.

[0089] (8) Toxicity test

[0090] 5 mL of human peripheral blood was collected from healthy donors of Guangzhou Overseas Chinese Hospital. All samples were collected with informed consent from the donors and approved by the Ethics Committee of Overseas Chinese Hospital. All operations and reagents after peripheral blood collection were sterile environments and sterile reagents. 4 mL of human peripheral blood lymphatic separation fluid was placed in a 15 mL centrifuge tube, and the peripheral blood was diluted with an equal volume of 1X PBS to the peripheral blood. The diluted peripheral blood was gently spread on the lymphatic separation fluid with a Pasteur pipette and centrifuged at 1500 rpm for 15 minutes at room temperature. The PBMC layer was gently aspirated with a Pasteur pipette and transferred to a new 15 mL centrifuge tube. After adding 6 mL of 1X PBS and mixing, it was centrifuged at 1000 rpm for 10 minutes at room temperature, and the supernatant was removed and washed again. After this step, the reagents used for sorting were all pre-cooled at 4°C. The following buffers used for sorting are all 1X PBS containing 4% FBS unless otherwise specified. Resuspend the cell mass with sorting buffer and transfer it to a 1.5EP tube for cell counting. Centrifuge at 350rcf and 4℃ for 5min and remove the supernatant. Add 80uL sorting buffer and 20uL sorting magnetic beads CD3 antibody for every 1*10e7 cells. Resuspend and mix the cell mass thoroughly and incubate at 4℃ for 15min. Mix gently every 5min. After incubation, add 1mL sorting buffer, centrifuge at 4℃ and 350rcf for 15min, remove the supernatant, repeat this step twice, and resuspend the cell suspension with 500uL sorting buffer for use. Fix the sorting column to the magnetic rack, place the waste liquid tube, moisten the column with 1mL sorting buffer 3 times, and then add the cell suspension to the sorting column. When the cell suspension is about to pass through the column, add 3mL sorting buffer to the sorting column for washing, and repeat 3 times. Remove the sorting column from the magnetic rack, add 1mL sorting buffer and place it in a new 15mL centrifuge tube. Use the piston to push the cells in the sorting column into the centrifuge tube together with the sorting buffer. Discard the foam at the end of the push. Add 5mL sorting buffer to the 15mL centrifuge tube, centrifuge at 350rcf for 5min at room temperature, remove the supernatant, add 2mL of RPMI 1640 medium containing 10% FBS to resuspend the cells and plant them in a 12-well plate to obtain human peripheral blood T cells. 400U / mL IL-2 and 10ul CD3 / CD28 monoclonal antibody per 1mL culture medium are still required to maintain and stimulate the survival and proliferation of T cells. The cells will be cultured in a sterile incubator at 5% CO2 and 37°C. After CD3 / CD28 stimulation culture for 48h, human peripheral blood T cells sufficient for subsequent experiments are harvested.

[0091] 50*10 were planted in each well of a 24-well plate. 4Human peripheral blood T cells were grouped according to the same dosage of T-ALL cell lines, namely, a blank control group Contrl (CTR), a PAMAM-G5 single-use group (PAMAM), a PAMAM-G5 packaged sgc8 group (PAMAM+sgc8), a PAMAM-G5 packaged siBCL11B group (PAMAM+siBCL11B), and a PAMAM-G5 packaged siBCL11B and sgc8 group (PAMAM+siBCL11B+sgc8). The same dose of reagents was added to each group and incubated for 48 hours. After that, T cell apoptosis was detected by flow cytometry, which was the same as the previous operation and will not be repeated.

[0092] 9) Statistical analysis

[0093] All data are expressed as mean ± standard deviation of three independent experiments, and statistical analysis was performed using GraphPad Prism 8.0 software. Statistical significance was analyzed using rank sum test and one-way analysis of variance, and p value was used (p value < 0.05 was considered to be significantly different. *, P < 0.05, **, P < 0.01, ***, P < 0.001, **** P < 0.0001).

[0094] 2. Experimental Results

[0095] 1. Figure 1 The structure and effectiveness mechanism of the design of the present invention are demonstrated, namely, siBCL11B that promotes apoptosis of T-ALL tumor cells and nucleic acid aptamer sgc8 that can target T-ALL tumor cells are encapsulated by PAMAM-G5, and siBCL11B is released into cells after PTK7-mediated endocytosis of nanoparticles to achieve specific transfection and promote apoptosis of T-ALL tumor cells.

[0096] The nanoparticle complexes formed by setting different ratios of PAMAM-G5 and siBCL11B were subjected to agarose gel electrophoresis. Figure 2 From the electrophoresis results shown, it can be seen that with the increase in the amount of PAMAM-G5, the number of nanocomplexes gradually increased. Finally, when PAMAM-G5:siBCL11B=3:1, all siBCL11B were combined with PAMAM-G5. Since the molecular weight of PAMAM-G5 is relatively large, it is manifested in the electrophoresis graph that the nucleic acid has not migrated at the loading well. At this time, the ratio is the most suitable.

[0097] According to this ratio, we set up different combinations of transfection groups and used siBCL11B labeled with cy5 (red fluorescence) and sgc8 labeled with FAM (green fluorescence). After incubation in the Molt4 cell line for 24 hours, we used confocal microscopy to locate the nucleic acid molecules inside and outside the cells. Figure 3 As shown, the complex formed by PAMAM-G5 and nucleic acid can stably deliver nucleic acid into Molt4 cells in complete medium with 10% serum.

[0098] 2. 48 h after applying the nanoparticle complex, we collected Molt4 / CCRF-CEM cells and extracted RNA. After reverse transcription into cDNA, we used RT-PCR to detect the expression of BCL11B in Molt4 cells. The results are as follows Figure 4 As shown. It can be found that compared with the CTR control group, PAMAM-G5 successfully delivered siBCL11B into cells and released siBCL11B, knocked down the expression of BCL11B at the transcriptional level, and the reduction was most obvious in the complex group with sgc8 added. At the same time, we also extracted the total protein of Molt4 / CCRF-CEM and detected the expression of BCL11B by Western blot. The results are shown in Figure 5 As shown. It can be found that compared with the CTR control group, the expression of BCL11B protein levels in the two groups of nanoparticle complexes encapsulating siBCL11B was reduced. This shows that the nanoparticle complex successfully transfected and delivered siBCL11B and knocked down the expression of BCL11B.

[0099] 3. We further detected the apoptosis of Molt4 / CCRF-CEM cells 48 hours after transfection with nanoparticle complexes. Figure 6 and Figure 8 As shown. It can be found that compared with the CTR control group, the apoptosis of Molt4 / CCRF-CEM cells in the group containing nanoparticle complexes encapsulated with siBCL11B increased, and the apoptosis rate of the group containing sgc8 was even higher. At the same time, we used CCK-8 to detect the viability of Molt4 / CCRF-CEM cells 48 hours after transfection with nanoparticle complexes. The results are shown in Figure 7 and Fig. 9 As shown. It can be found that compared with the CTR control group, the activity of Molt4 / CCRF-CEM cells in the group of nanoparticle complexes encapsulated with siBCL11B was reduced, and the group of cells with added sgc8 was even lower. This shows that the nanoparticle complex can promote T-ALL tumor cell apoptosis and inhibit cell proliferation activity by delivering siBCL11B, and sgc8 can enhance the efficiency of the nanoparticle complex.

[0100] 4. We further constructed a T-ALL PDX model by transplanting it into BND-G mice and administered the drug according to the protocol. At the end of the experiment, we obtained femoral bone marrow cells from mice in each group and used flow cytometry to detect the expression ratio of human CD45 in bone marrow cells in each group. The results are as follows: Fig.10 As shown. It can be found that compared with the CTR control group, the human CD45 expression ratio of the nanoparticle complex group encapsulated with siBCL11B is reduced, that is, the tumor load is reduced, and the tumor load of the group with sgc8 added is even lower. This shows that the nanomedicine designed in this patent can still work in the in vivo environment simulating T-ALL, and sgc8 can enhance the efficiency of the nanoparticle complex.

[0101] 5. We further performed the same intervention on primary T cells collected and sorted from healthy donors according to the dosage and grouping of the cell line experiment, and used flow cytometry to detect the effect of transfection of nanoparticle complexes on apoptosis of normal T cells 48 hours later. The results are as follows: Fig.11 It can be found that the nanoparticles designed in this patent have little effect on the apoptosis rate of normal T cells at a dose that exerts an anti-tumor effect.

[0102] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the described embodiments. Any other changes, modifications, substitutions, combinations, and simplifications made without departing from the spirit and principles of the present invention shall be equivalent replacement methods and shall be included in the protection scope of the present invention.

Claims

1. A nanoparticle composite, characterized in that: The invention is prepared by compounding a polyamide-amine dendritic polymer and nucleic acid, wherein the nucleic acid is aptamer sgc8 and siBCL11B; and the siBCL11B refers to siRNA that targets and inhibits the BCL11B gene.

2. The nanoparticle composite according to claim 1, characterized in that: The polyamidoamine dendritic polymer is selected from PAMAM-G5.

3. The nanoparticle composite according to claim 1, characterized in that: The sequence of the aptamer sgc8 is 5'-ATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGT TAGA-3'.

4. The nanoparticle composite according to claim 1, characterized in that: The sequence of the siBCL11B is 5'-GCACAACAUGCAAGCAGCCCUUCAA-3'.

5. The nanoparticle composite according to any one of claims 1 to 4, characterized in that: The molar ratio of the polyamide-amine type dendritic polymer to the nucleic acid is 2 to 4:

1.

6. The nanoparticle composite according to claim 5, characterized in that: The molar ratio of the polyamidoamine dendritic polymer to the nucleic acid is 3:

1.

7. The nanoparticle composite according to any one of claims 1 to 4, characterized in that: The molar ratio of the aptamer sgc8 to siBCL11B is 3-5:

1.

8. The nanoparticle composite according to claim 7, characterized in that: The molar ratio of the aptamer sgc8 and siBCL11B is 4:

1.

9. The method for preparing the nanoparticle composite according to any one of claims 1 to 8, characterized in that: The polyamidoamine dendrimer solution, the aptamer sgc8 solution and the siBCL11B solution were fully mixed, centrifuged instantaneously and incubated at room temperature to form a stable nanoparticle structure.

10. Use of the nanoparticle complex according to any one of claims 1 to 8 in the preparation of a drug for treating acute T-lymphocytic leukemia.

Citation Information

Patent Citations

  • Aptamer and new use of derivative thereof

    CN101537189A

  • SiRNA-935 capable of inhibiting BCLL11B expression and tumorous T cell proliferation and use thereof

    CN101696413A

  • Self-assembled nano-gene vector compound based on PAMAM (Poly Amido-Amine) and preparation method thereof

    CN103536934A

  • Immune drug and application thereof in tumor immunotherapy

    CN113018433A

  • Leukemia targeted therapy preparation as well as preparation method and application thereof

    CN120131981A